Biotech Values

[caravon]

Mark Schoenebaum, a high-profile analyst for ISI and a longtime booster of Gilead's blockbuster hepatitis C efforts, gives the biotech the inside track to one of the Holy Grails in biotech: one pill that can conquer the entire global market.

But is it really necessary to have a single pill for all HCV genotypes? I am trying to say that it is nice to have a single antibiotic for all kind of bacterial infections but it always comes together with undesirable side-effects and consequences.

Furthermore, having a pill for a specific HCV genotype can potentially cut treatment time well below even 4 weeks. For a “typical” HCV patient, it will make a lot of sense.